news

First patients dosed in GSK’s Phase III meningitis vaccine trial

7
SHARES

The trial will assess the safety, tolerability and immunogenicity of the five-in-one MenABCWY vaccine in participants aged 10 to 25.

adolescent woman recieving a vaccination in the top of her arm

GSK (GlaxoSmithKline) reports it has dosed the first patients enrolled on the Phase III trial testing its five-in-one meningitis vaccine candidate.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The MenABCWY vaccine will be administered to participants aged 10 to 25 at sites in the US, EU, Turkey and Australia as part of the multicentred trial. The study will evaluate the safety, tolerability and immunogenicity of MenABCWY compared to comparable meningitis vaccine products licenced to the company by Bexsero and Menveo and aims to enrol 3,650 individuals.

The novel candidate targets five meningitis serogroups – A, C, W, Y and B – which account for nearly all cases of invasive meningococcal disease (IMD). If successful, it would be the first five-in-one combination vaccine for meningitis available anywhere in the world.

“Current [US Food and Drug Administration] FDA-approved meningitis vaccines help protect young persons who complete a four-injection regimen during adolescence but, unfortunately, only a small percentage receive all four,” said Dr Charles Andrews, study investigator and director of clinical research at the Diagnostic Research Group in San Antonio, Texas, US. “The investigational vaccine has the potential to reduce the number of injections and thereby improve completion rates.”

According to the enterprise, adolescents and young adults are more likely to contract meningitis due to their close contact with each other. They added that, although meningococcal disease is uncommon, studies have shown that the relative risk of contracting meningitis B was up to five times higher in university students aged 18-24 compared with peers not attending university.

“We are excited to reach this important milestone in the development of a five-in-one MenABCWY vaccine. It offers the potential to help protect against all five vaccine-preventable serogroups with one combined product… This could reduce complexity and the potential confusion of needing two different types of vaccines, along with the added benefit of fewer injections for each patient,” said Barbara Howe, vice president and director, vaccine medical and clinical US, GSK.

Related organisations

Related drugs

Related diseases & conditions

Share via
Share via